NuPathe (PATH)
Add to Watchlists Create an Alert
3.10
-0.04 -1.27%
NASDAQ
May 23, 4:59PM
BATS Real time
Currency in USD
NuPathe Interest Expense:
0.286M for Dec. 31, 2012NuPathe Historical Interest Expense Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.286M |
| Sept. 30, 2012 | 0.446M |
| June 30, 2012 | 0.395M |
| March 31, 2012 | 0.453M |
| Dec. 31, 2011 | 0.509M |
| Sept. 30, 2011 | 0.522M |
| June 30, 2011 | 0.249M |
| March 31, 2011 | 0.203M |
| Dec. 31, 2010 | 0.179M |
| Sept. 30, 2010 | 2.093M |
| June 30, 2010 | 1.435M |
| March 31, 2010 | 0.0113M |
| Dec. 31, 2009 | 0.0063M |
| Sept. 30, 2009 | 1.208M |
| June 30, 2009 | 0.0497M |
| March 31, 2009 | 0.056M |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
A higher interest expense means that the company is paying more to its debtors. In general, a company's capital structure with a heavier debt focus will have higher interest expenses. Liquidity ratios such as EBIT/Interest Expense can help investors see if increasing Interest Expenses are problematic.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
PATH Interest Expense Benchmarks
| Companies | |
|---|---|
| Cadence Pharmaceuticals | 1.10M |
| Cytori Therapeutics | 0.804M |
| ARCA biopharma | 0.001M |
PATH Interest Expense Rankings
| Overall |
59th percentile 3263 of 8006 |
| Sector |
38th percentile 420 of 686 in Healthcare |
| Industry |
33rd percentile 166 of 248 in Biotechnology |
PATH Interest Expense Range, Past 5 Years
| Minimum | 0.0063M | Dec 2009 |
| Maximum | 2.093M | Sep 2010 |
| Average | 0.5063M |
